Search Results

The phase II RELATIVITY-104 trial assessed the combination of nivolumab (NIVO) and relatlimab (RELA), a LAG-3-blocking antibody, alongside chemotherapy (PDCT) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). In this randomized trial, patients receiving NIVO + RELA + PDCT demonstrated a higher overall response rate (ORR) (51.3%) compared to NIVO + PDCT […]

Severe haemophilia A (HA), defined as baseline factor VIII (FVIII) levels of <1%, results in traumatic and spontaneous bleeding episodes, which occur primarily in the joints, in addition to the muscles, soft tissue and the central nervous system. Prophylactic treatment is needed to prevent complications such as joint arthropathy.1 Treatment for HA has historically been achieved […]

Multiple myeloma (MM) is the second most common haematological malignancy, with upwards of 35,000 diagnoses in the USA each year.1,2 It remains a leading cause of blood cancer–related mortality worldwide, and although therapeutic advances have allowed for significant improvements in the median overall survival,3,4 the majority of patients still experience cycles of relapse that are eventually fatal.5 While patients with MM are living longer, a subgroup with high-risk disease at diagnosis still does poorly, with a median […]

Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for 15% of all breast cancers.1 This breast cancer subtype was historically associated with poor outcomes; however, the development of HER2-directed therapies has dramatically improved outcomes for patients with both early and advanced HER2+ disease.2 Currently, there are several types of HER2-targeted agents approved for the […]

Acute myeloid leukaemia (AML) is a heterogeneous haematological malignancy characterized by the presence of ≥20% blasts in bone marrow or peripheral blood or the presence of defined genetic abnormalities.1 In 2020, there were an estimated 21,450 new patients with AML and 11,180 AML-related deaths in the USA.2 Most mutated myeloid stem cells proliferate due to genetic alterations, […]

Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) benefits.2 Chemotherapy-induced myelosuppression is often managed with granulocyte-colony stimulating factors (G-CSFs) and erythropoiesis-stimulating agents (ESAs) […]

Treatment options for myeloma have rapidly expanded in the past decade and, as with many cancers, the number of oral drug options has increased considerably. Given the more limited number of cancer hospitals, patients often must travel considerable distance to get to their closest cancer centre, which places a significant burden on receiving adequate therapy. […]

Multiple myeloma (MM) remains largely an incurable disease with only a small percentage of patients achieving long-term remission.1 Here, we highlight some of the major studies on MM presented at the American Society of Hematology meeting in December 2021. Monoclonal gammopathy of undetermined significance and smouldering myeloma The Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) […]

In December 2019, an outbreak of pneumonia of unknown aetiology was observed in the Chinese city of Wuhan, capital of Hubei province. By January 2020, this outbreak was attributed to a novel virus classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the latest member of the coronaviridae family responsible for major infectious outbreaks, including […]